Tectonic Therapeutic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies designed to modulate G-protein coupled receptors (GPCRs) using its proprietary GEODe platform technology. The company's pipeline includes TX45, an Fc-relaxin fusion molecule targeting pulmonary hypertension and heart failure; TX2100, an APJ receptor antagonist antibody for hereditary hemorrhagic telangiectasia; and a bispecific GPCR modulator program for fibrotic diseases. Tectonic has no current revenue and relies on third-party contract manufacturers for drug development and production; the company generates future value through successful clinical trials, regulatory approvals, and eventual commercialization of its product candidates to patients with cardiovascular, pulmonary, and rare genetic disorders where treatment options are limited.